
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax Inc. has revised its financial outlook for fiscal year 2025, slightly increasing its revenue framework from $1-$1.05 billion to $1.04-$1.06 billion, indicating a positive trend in projected financial performance. The company has recorded $225 million in milestones year-to-date, with an expectation of an additional $50 million contribution in the fourth quarter for U.S. and EU marketing authorization transfers, showcasing strong operational progress. Furthermore, Novavax's working capital has improved to $544.7 million, reflecting better financial health that facilitates continued investment in its core vaccine development initiatives.
Bears say
Novavax Inc has reported a significant reduction in cash equivalents, declining from $938.2 million to $778.2 million, indicating a concerning operational cash burn that may jeopardize ongoing projects. The company also experienced a 17% year-over-year revenue decline, largely due to a transition in commercial responsibility which resulted in a substantial decrease in revenue from $71 million in the third quarter of 2024, reflecting a 55% year-over-year drop. Furthermore, if their vaccine candidates, such as NanoFlu, fail to demonstrate a competitive edge over existing options, the company may struggle to achieve revenue generation, worsening its financial outlook.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares